Skopos Labs, Inc. Supernus Pharmaceuticals, Inc. Transaction History
Skopos Labs, Inc.
- $497 Million
- Q2 2025
A detailed history of Skopos Labs, Inc. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Skopos Labs, Inc. holds 222 shares of SUPN stock, worth $12,543. This represents 0.0% of its overall portfolio holdings.
Number of Shares
222
Previous 222
-0.0%
Holding current value
$12,543
Previous $7,000
14.29%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding SUPN
# of Institutions
318Shares Held
61MCall Options Held
18.4KPut Options Held
0-
Black Rock Inc. New York, NY10.4MShares$587 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.21MShares$351 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.81MShares$272 Million2.66% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$171 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.76MShares$156 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $3.02B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...